SCHEMBL21055396

SCHEMBL21055396

Cc1ccc(S(=O)(=O)O[C@H]2CC[C@H](Oc3ccccc3F)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.49
FPR2 P25090 1/20 0.45
PROKR1 Q8TCW9 1/20 0.45
HTR2C P28335 1/20 0.43
CYP1A2 P05177 2/20 0.41
HTR1A P08908 3/20 0.41
SLC6A2 P23975 3/20 0.41
SLC6A3 Q01959 2/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
VDR P11473 1/20 0.40
HTR6 P50406 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
LPAR1 Q92633 1/20 0.38
LPAR5 Q9H1C0 1/20 0.38
GPR6 P46095 1/20 0.38
CYP2C9 P11712 1/20 0.37
PSEN1 P49768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21055393 1.00 CYP2D6 (0.49) CYP2D6FPR2PROKR1HTR2CCYP1A2
SCHEMBL21055453 0.82 CYP2D6 (0.52) CYP2D6FPR2PROKR1CYP1A2CYP2C19
SCHEMBL21055454 0.82 CYP2D6 (0.52) CYP2D6FPR2PROKR1CYP1A2CYP2C19
SCHEMBL657896 0.81 CYP2D6 (0.67) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL10376015 0.81 CYP2D6 (0.67) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL21055558 0.81 CYP2D6 (0.53) CYP2D6FPR2PROKR1HTR2CCYP1A2
SCHEMBL21055560 0.81 CYP2D6 (0.53) CYP2D6FPR2PROKR1HTR2CCYP1A2
SCHEMBL3201810 0.80 HTR2C (0.63) FPR2PROKR1HTR2CLMNAMEN1
SCHEMBL21055269 0.78 CYP2D6 (0.51) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL21055271 0.78 CYP2D6 (0.51) CYP2D6CYP1A2CYP3A4CYP2C19VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
WO-2019113190-A1 BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES ARRAY BIOPHARMA INC. (US) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 CYP2D6 3215/4885FPR2 2081/4885PROKR1 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.